Chimeric Antigen Receptor T-Cell Therapy for Lymphoma in Korea: Current Status, Challenges, and Future Directions (ICBMT 2026) - Oct 8, 2026 - Abstract #JS03-2; Pres time: Sep 18, 2026; 10:35 AM - 11:00 AM; Location: Room A(1F); "Although tisagenlecleucel has been approved and reimbursed, access to other CD19-directed CAR T-cell products remains limited, as they have received regulatory approval but are not yet reimbursed. The lecture will also outline ongoing domestic and investigator-initiated efforts to develop and evaluate CAR T-cell therapies, which aim to broaden access to and improve the outcomes of CAR T-cell therapy for lymphoma in Korea."
CAR T-Cell Therapy • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma
|